PD-L1 antibody Clinical Trials
2 recruitingDrug
Phase 22Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Recurrent Cervical CancerMetastatic Cervical CancerPersistent Cervical Cancer
N.N. Alexandrov National Cancer Centre120 enrolled1 locationNCT07472153
Recruiting
Phase 2
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Hepato Cellular Carcinoma (HCC)
West China Hospital36 enrolled1 locationNCT06742424